Skip to Content

CAR-T Cell Therapy as Second-Line Treatment for Elderly Patients with Relapsed/Refractory Large B-Cell Lymphoma

Mats Jerkeman discusses in this MEDtalk the ZUMA-7 trial’s subgroup analysis from the ASH meeting. This trial compared CAR-T cell treatment to standard autologous stem cell transplant in first relapse diffuse large B-cell lymphoma (R/R LBCL) elderly patients (above 65, including those over 70). Zuma-7 shows that CAR-T cell therapy significantly improved progression-free and overall survival in this subgroup. This finding suggests CAR-T cell therapy as a viable second-line treatment for elderly R/R LBCL patients.

Mats Jerkeman

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top